Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.48 |
| ▸ | CPB1 | P15086 | 4/20 | 0.48 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30268827 | 0.95 | PLA2G4A (0.52) | PLA2G4ACPB2CPB1KDM5AKDM5B | |
| SCHEMBL27781551 | 0.93 | PLA2G4A (0.54) | PLA2G4ACPB2CPB1KDM5AKDM5B | |
| SCHEMBL27781577 | 0.93 | PLA2G4A (0.54) | PLA2G4ACPB2CPB1KDM5AKDM5B | |
| SCHEMBL710279 | 0.89 | KDM5A (0.54) | PLA2G4ACPB2CPB1KDM5AKDM5B | |
| SCHEMBL27781554 | 0.85 | CPB2 (0.47) | PLA2G4ACPB2CPB1KDM5AKDM5B | |
| SCHEMBL26813651 | 0.82 | CPB2 (0.45) | PLA2G4ACPB2CPB1KDM5AKDM5B | |
| SCHEMBL151394 | 0.82 | SMYD3 (0.50) | PLA2G4ACPB2CPB1KDM5AKDM5B | |
| SCHEMBL28034307 | 0.81 | PLA2G4A (0.41) | PLA2G4ACPB2CPB1KDM5AKDM5B | |
| SCHEMBL29852373 | 0.81 | TNF (0.47) | PLA2G4ALMNACYP1A2 | |
| SCHEMBL7265607 | 0.80 | PLA2G4A (0.39) | PLA2G4ACPB2KDM5AKDM5BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| CN-101189228-A | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors | PFIZER PROD INC (US) | 2008-05-28 | — | — | CN | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-3551632-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018108910-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| CN-101679293-A | Urocanic acid derivatives useful for the treatment of immune-related and inflammatory diseases | VALETTA HEALTH B V | 2010-03-24 | — | — | CN | disclosed |
| CN-101189228-A | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors | PFIZER PROD INC (US) | 2008-05-28 | — | — | CN | disclosed |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2003051795-A2 | RESIN-BONDED ISONITRILES | MORPHOCHEM AG (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222321-A1 | Inhibitors of akt activtiy | PIK3CA, PIK3CD, INPP5D | PLA2G4A 765/4885CPB2 2627/4885CPB1 1635/4885 |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | PLA2G4A 2510/4885CPB2 3597/4885CPB1 2336/4885 |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | SLC1A2, SLC1A1, GLRA1 | PLA2G4A 2340/4885CPB2 3648/4885CPB1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.